



BIOSENSORS
INTERNATIONAL

FOR IMMEDIATE RELEASE

Biosensors International Names Kevin Sayer Chief Financial Officer

Formerly CFO at Minimed and Specialty Laboratories

Newport Beach, California, 12 April 2007 - Biosensors International Group Ltd. (“Biosensors” or the “Company”, Bloomberg: BIG SP) today announced that it has hired veteran financial executive Kevin R. Sayer as Chief Financial Officer, effective immediately. Mr. Sayer, who is based in the Company’s office in Newport Beach, California, brings to Biosensors more than 12 years of executive-level financial management experience, including positions as chief financial officer of New York Stock Exchange and Nasdaq-listed public companies. He will report to Biosensors’ Chairman and Chief Executive Officer, Yoh-Chie Lu.

Mr. Sayer, 49, has spent several years working as an independent healthcare and medical technology industry consultant, focusing primarily on strategic planning and business development activities. From 2004 to 2005 he was Executive Vice President and Chief Financial Officer of Specialty Laboratories, Inc., a NYSE-listed company offering clinical reference laboratory services, where he led the implementation of policies and procedures for Sarbanes-Oxley compliance and co-led development of the company’s strategic business plan, including analysis and evaluation of alternative business lines, acquisition targets and financing alternatives.

“Kevin’s extensive financial and corporate transactions experience with early-stage and growth-phase companies in the medical industry will play a key role in the execution of Biosensors’ business strategy,” said Mr. Lu. “His background and knowledge will also be important to the completion of our conversion from International Financial Reporting Standards (IFRS) to U.S. Generally Accepted Accounting Principles (US GAAP), which will provide the financial framework to support the Company’s expected growth. I am also confident that Kevin’s reporting and compliance experience from working in NYSE and Nasdaq-listed companies, and experience in the mergers and acquisitions area, will contribute to our near- and long-term goal of creating greater value for our shareholders.”

From 1994 to 2001, Mr. Sayer was the Chief Financial Officer of Minimed, Inc., a Nasdaq-listed medical device company focused on diabetes management. During his tenure at Minimed, Mr. Sayer managed multiple financing and strategic transactions and played a central role in the 2001 acquisition of Minimed, Inc., by NYSE-listed Medtronic, Inc. From 2001 to 2002, he co-led the integration team for the newly-combined entity within Medtronic and assumed executive responsibilities over operations as vice president and general manager of their External Pump and Disposable Products business unit.

Mr. Sayer is a director and Audit Committee Chairman for Akesis Pharmaceuticals, an early-stage biopharmaceutical company engaged in development and commercialization of therapies to treat diabetes and other carbohydrate intolerances.

Mr. Sayer also spent 11 years in public accounting with Ernst & Young, where he became a Certified Public Accountant. He earned a Master’s Degree in Accounting and Information Systems concurrently with a Bachelor’s Degree in Accounting, both from Brigham Young University.

Media & Investor Relations

Singapore

Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 62135708
Email: cm.loh@biosensors.com

United States

Allen&Caron Inc.

Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

MORE – MORE – MORE

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary antirestenotic drug. It is pursuing three separate drug-eluting stent programs, *BioMatrix*[®], *Axxion*[™], and *BioMatrix*[®] *Freedom*[™], a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

Forward Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

###